Ask AI
ProCE Banner Activity

CE / CME

New Treatments on the Horizon: Cancer Conversations on Novel Mechanisms and Emerging Treatment Options in mCRPC

Video

In this certified on-demand webcast, experts discuss novel mechanisms of resistance in metastatic castration-resistant prostate cancer (mCRPC) and explore emerging therapies—including EZH2 and CYP11 inhibitors, PROTAC degraders, and cell surface–targeted treatments—highlighting ongoing clinical trials and the importance of precision medicine, multidisciplinary care, and equitable access to clinical trials.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

ABIM MOC: maximum of 1.50 Medical Knowledge MOC points

Released: June 24, 2025

Expiration: December 23, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC in partnership with ZERO Prostate Cancer

ProCE Banner

Supporters

Supported by educational grants from Novartis Pharmaceuticals Corporation and Pfizer, Inc.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Partners

ZERO Prostate Cancer

ProCE Banner

Target Audience

This educational activity is intended for medical oncologists, urologists, and other healthcare professionals who care for patients with prostate cancer.

Program Learning Goal

The goal of this activity is to improve the knowledge and competence of learners in integrating novel therapies into the care of patients with mCRPC. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Educate colleagues and patients on the mechanism of action and rationale for novel therapies under investigation in mCRPC

  • Evaluate new data on novel agents and therapeutic approaches for patients with mCRPC

  • Identify patients with mCRPC who may be eligible for ongoing clinical trials of novel therapies

  • Implement strategies to support equitable access to clinical trials of novel therapies in Black and other underserved patient populations with mCRPC

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Alicia K. Morgans, MD, MPH, FASCO: consultant/advisor/speaker: Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Curium, Exact Science, Exelixis, Janssen, Lantheus, Merck, Novartis, Pfizer, Sumitomo, Telix, Tolmar.

Charles J. Ryan, MD: consultant/advisor/speaker: Bayer, Oric, Pfizer.

Neal D. Shore, MD, FACS: consultant/advisor/speaker: Accord, Alessa, Amgen, Antev, Arquer, Asieris, Astellas, AstraZeneca, Aura Biosciences, Bayer, BioProtect, Bristol Myers Squibb, CG Oncology, Clarity, Dendreon, Exact Imaging, Ferring, Fize Medical, Glytherix, Invitae, Janssen, Lantheus, Lilly, MDXHealth, Merck, Minomic, Myriad, Novartis, Photocure, Pfizer, Preview, Promaxo, Propella, Protara, Sanofi Genzyme, Siemens, Specialty Networks, Sumitomo, Telix, Tolmar, Tutelix, Urogen.

The planners and content peer reviewers from Clinical Care Options, LLC and Zero Prostate Cancer do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 24, 2025, through December 23, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and ZERO Prostate Cancer. Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification 

A blue and black sign with white textDescription automatically generated

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.